BIOGEN INC. Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax
BIOGEN INC. (BIIB) had Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax of $1.30 million as of 2018-12-31, per its 10-K filed 2019-02-06.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax · last filed 2019-02-06
- 2018-12-31: Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax $1.30M.
- 2018-03-31: Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax $500.00K.
- 2017-12-31: Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax $2.30M.
- 2017-09-30: Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax $4.10M.
| Period end | Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax |
|---|---|
| 2018-12-31 | $1.30M 10-K · filed 2019-02-06 |
| 2018-03-31 | $500.00K 10-Q · filed 2018-04-24 |
| 2017-12-31 | $2.30M 10-K · filed 2019-02-06 |
| 2017-09-30 | $4.10M 10-Q · filed 2017-10-24 |
| 2017-06-30 | $3.50M 10-Q · filed 2017-07-25 |
| 2017-03-31 | $4.30M 10-Q · filed 2017-04-25 |
| 2016-12-31 | $2.90M 10-K · filed 2018-02-01 |
| 2016-09-30 | $8.20M 10-Q · filed 2016-10-26 |
| 2016-06-30 | $13.20M 10-Q · filed 2016-07-21 |
| 2016-03-31 | $6.90M 10-Q · filed 2016-04-21 |
| 2015-12-31 | $300.00K 10-K · filed 2017-02-02 |
| 2015-09-30 | $2.30M 10-Q · filed 2015-10-21 |
| 2015-06-30 | $1.70M 10-Q · filed 2015-07-24 |
| 2015-03-31 | $1.90M 10-Q · filed 2015-04-24 |
| 2014-12-31 | $700.00K 10-K · filed 2016-02-03 |
| 2014-09-30 | $1.40M 10-Q · filed 2014-10-22 |
| 2014-06-30 | $1.10M 10-Q · filed 2014-07-23 |
| 2013-12-31 | $400.00K 10-K · filed 2015-02-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |